https://doi.org/10.4081/btvb.2024.145
Thrombin generation assay in COVID-19 patients shows a hypocoagulable pattern
Submitted: 23 June 2024
Accepted: 2 October 2024
Published: 22 October 2024
Accepted: 2 October 2024
Abstract Views: 915
PDF: 87
Supplementary: 64
Supplementary: 64
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Patients with COVID-19 often exhibit coagulopathy, which can significantly impact prognosis. Therefore, investigating coagulation in this context is clinically relevant. The thrombin generation assay (TGA) provides comprehensive data on individual clotting patterns. In our study, we utilized a calibrated automated thrombogram to globally assess coagulation in COVID-19 patients. The study included 67 COVID-19 patients (40 hospitalized in the medical ward and 27 in intensive care units) and 45 blood donors for comparison. Our analysis revealed significant differences in TGA parameters (lag time, time-to-peak, thrombin peak, and endogenous thrombin potential) between patients and blood donors, suggesting a hypocoagulable state in the former. Specifically, COVID-19 patients exhibited prolonged lag time and time-to-peak values, as well as lower thrombin peak and endogenous thrombin potential compared to blood donors (Mann-Whitney test: p<0.05); notably, no significant differences in thrombin generation were observed based on the clinical setting. These findings suggest a reduced capacity for thrombin generation, indicating a consumptive coagulopathy in COVID-19 patients and that in this context, thrombosis is primarily attributable to localized effects in the lungs, platelet activation, and/or prothrombotic endothelial dysfunction. The thrombin generation assay is instrumental in defining coagulation patterns in COVID-19 and may also be applicable to other infectious diseases.
Gerber GF, Chaturvedi S. How to recognize and manage COVID-19-associated coagulopathy. Hematology Am Soc Hematol Educ Program 2021:614-20.
DOI: https://doi.org/10.1182/hematology.2021000297
Devreese KMJ. COVID-19-related laboratory coagulation findings. Int J Lab Hematol Suppl 1:36-42.
DOI: https://doi.org/10.1111/ijlh.13547
Tiscia GL, Favuzzi G, De Laurenzo A, et al. Reduction of ADAMTS13 levels predicts mortality in SARS-CoV-2 patients. TH Open 2020;4:e203-e206.
DOI: https://doi.org/10.1055/s-0040-1716379
Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clinical Chemistry 2016;62: 699-707.
DOI: https://doi.org/10.1373/clinchem.2015.248625
Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4-15.
DOI: https://doi.org/10.1159/000071636
White D, MacDonald S, Edwards T, et al. Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays. Int J Lab Hematol 2021;43:123-30.
DOI: https://doi.org/10.1111/ijlh.13329
Marongiu F, Grandone E, Barcellona D. Pulmonary thrombosis in 2019-nCoV pneumonia? J Thromb Haemost 2020;18:1511-13.
DOI: https://doi.org/10.1111/jth.14818
Wójcik K, Bazan-Socha S, Celejewska-Wójcik N, et al. Decreased protein C activity, lower ADAMTS13 antigen and free protein S levels accompanied by unchanged thrombin generation potential in hospitalized COVID-19 patients. Thromb Res 2023;223:80-86.
DOI: https://doi.org/10.1016/j.thromres.2023.01.016
Cohen O, Landau N, Avisahai E, et al. Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients. Acta Haematol 2023;146:151-60.
DOI: https://doi.org/10.1159/000527581
Campello E, Bulato C, Spiezia L, et al. Thrombin generation in patients with COVID-19 with and without thromboprophylaxis. Clin Chem Lab Med 2021;59:1323-30.
DOI: https://doi.org/10.1515/cclm-2021-0108
Gris JC, Guillotin F, Dos Santos TP, et al. Prognostic value of an automated thrombin generation assay in COVID-19 patients entering hospital: A multicentric, prospective observational study. Thromb Res 2023;222:85-95.
DOI: https://doi.org/10.1016/j.thromres.2022.12.019
Kelliher S, Weiss L, Cullivan S, et al. Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. J Thromb Haemost 2022;20:1008-14.
DOI: https://doi.org/10.1111/jth.15660
Nougier C, Benoit R, Simon M, et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost 2020;18:2215-9.
DOI: https://doi.org/10.1111/jth.15016
Vermeiren P, Vandevelde A, Peperstraete H, Devreese KMJ. Monitoring of heparin therapy beyond the anti-Xa activity assay: Evaluation of a thrombin generation assay. Int J Lab Hematol 2022;44:785-95.
DOI: https://doi.org/10.1111/ijlh.13836
Binder NB, Depasse F, Mueller J, et al. Clinical use of thrombin generation assays. J Thromb Haemost 2021;19:2918-29.
DOI: https://doi.org/10.1111/jth.15538
van de Berg TW, Hulshof AM, Nagy M, et al. Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability. Thromb Res 2021;201:84-9.
DOI: https://doi.org/10.1016/j.thromres.2021.02.026
Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost 2020;18:2103-9.
DOI: https://doi.org/10.1111/jth.14975
Thachil J. Lessons learnt from COVID-19 coagulopathy. EJHaem 2021;2:577584.
DOI: https://doi.org/10.1002/jha2.228
Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023-6.
DOI: https://doi.org/10.1111/jth.14810
Supporting Agencies
Italian Ministry of HealthHow to Cite
Tiscia, G. L., Colaizzo, D., De Laurenzo, A., Cappucci, F., Fischetti, L., Chinni, E., … Grandone, E. (2024). Thrombin generation assay in COVID-19 patients shows a hypocoagulable pattern. Bleeding, Thrombosis and Vascular Biology, 3(3). https://doi.org/10.4081/btvb.2024.145
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Most read articles by the same author(s)
- Giovanni Tiscia, Elvira Grandone, Talking about assisted reproductive techniques and thromboembolic risk: everything we always wanted to know , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Francesco Marongiu, Elvira Grandone, Silvia Marongiu, Antonella Mameli, Doris Barcellona, Stroke in women: anticoagulation in a complicated puzzle , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Roberto Mario Santi, Annamaria Fulghesu, Ezio Zanon, Erica De Candia, Elvira Grandone, Giancarlo Di Renzo, Claudia Succu, Valentina Tosto, Vincenzina Bruni, Paolo Gresele, Diagnosis and management of abnormal uterine bleeding in adolescence , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 1 (2024)
- Daniela Poli, Riccardo Tartaglia, Doris Barcellona , Paolo Bucciarelli , Antonio Ciampa, Elvira Grandone, Giuseppe Malcangi, Giuseppe Rescigno, Vincenzo Toschi, Sophie Testa, Alessandro Squizzato, Attitude to clinical research among health professionals affiliated with the Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
Similar Articles
- Anna Maria Gori, Eleonora Camilleri, Alessia Bertelli, Angela Rogolino, Francesca Cesari, Elena Lotti, Tommaso Capobianco, Walther Iannotti, Betti Giusti , Rossella Marcucci, Pleiotropic effects of anti-thrombotic therapies: have direct oral anticoagulants any anti-inflammatory effect? , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Boris Shenkman, Ivan Budnik, Yulia Einav, Interaction between adenosine diphosphate receptors and protein-kinase C isoforms in platelet adhesion under flow condition , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Vincenzo Sammartano, Adele Santoni, Elisabetta Zappone, Paola Calzoni, Daniela Fineschi, Eleonora Franceschini, Federico Caroni, Anna Sicuranza, Monica Bocchia, Luca Puccetti, A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Gualtiero Palareti, Paolo Prandoni, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Alberto Tosetto, Lorenza Bertù, Sophie Testa, Vittorio Pengo, Walter Ageno, Ida Martinelli, Benilde Cosmi, Eugenio Bucherini, Daniela Poli, Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Giovanni Di Minno, Gaia Spadarella, Ilenia Lorenza Calcaterra, Giancarlo Castaman, Paolo Simioni, Raimondo De Cristofaro, Cristina Santoro, Flora Peyvandi, Matteo Di Minno, The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
You may also start an advanced similarity search for this article.
